DRUG PRIOR AUTHORIZATION COMMITTEE MEETING

December 15, 2016

James C. Kirkpatrick State Information Center - 600 West Main Street, Jefferson City, MO

|  |  |
| --- | --- |
| **Committee Members Present**Conrad Balcer, D.O. Laine Young-Walker, M.D.Jennifer Kemp-Oestriech, Pharm D Patrick Bryant, Pharm DLaura Kingsley, Pharm DMorgan Sperry, Pharm D - *\*Non-voting member this mtg* | **MO HealthNet Staff Present:**Mark Roaseau, R.Ph, Clinical Pharmacist Stephen Calloway, R.Ph, Director of Pharmacy Jenna McTeer, RN, Clinical Management Angela Wilson, Manager, Band IMegan Goldthrite, Administrative Office Support Assistant Frances (Franki) Moseley, Administrative Office Support Assistant Dr. Timothy Kling, MD, Assistant Medical Director EBU |

**Contractors in Attendance:** Katie Wilbers, Pharm D, Xerox Josh Moore, Pharm D, Xerox Luke Boehmer, Pharm D, Xerox Rick Pope, Pharm D, Magellan

|  |  |  |
| --- | --- | --- |
| **Others Attending:** |  |  |
| Rob Kilo, Biogen Matt Seibt, BiogenRobert Robey, IndiviorJerod Downing, Purdue Pharma, LP Chet Steckler, Purdue Pharma, LP Mike LaFond, AbbvieSteve Naert, Lilly John Kirby, SanofiMary Jo DeFlorio, Janssen | Derele Bush, AGN Taylor Bradshaw, AGNPatrick Parikh, Sarepta Therapeutics Patrick Wies, Sarepta Therapeutics Kelly Smallmon, SLU School of Law Jimi Road, NovartisRose Mullen, Alkermes Evan Rushing, AlkermesLiz Weber, Rhoads Company | Brian Strickland, Gilead Mike Holmes, Sunovion Todd Herman, Merck Phil King, PfizerGeri Roling, Wipro Chelsea Pendleton, Wipro |

Sign-in sheet on file for review.

|  |  |
| --- | --- |
| **Welcome, Introductions and Opening Remarks** | Conrad Balcer, D.O., Acting Committee Chairman, called the meeting to order. Stephen Calloway introduced Frances (Franki) Moseley as our new Administrative Office Support Assistant (AOSA) in the Pharmacy Program. Stephen Calloway welcomed a new PA committee member, Laura Kingsley, Pharm D. Dr. Kingsley is a pharmacist/owner at Kilgore’s Medical Pharmacy. |
| **Minutes Approval** | Minutes of the September 15, 2016, meeting were reviewed and approved. Laine Young-Walker, MD, motioned and Pat Bryant seconded the motion. (See Roll Call Vote) |
| **Pharmacy Program/Budget Update** | Stephen Calloway made a powerpoint presentation for the Committee. The presentation contained graphs representing historical and current expenditures, expenditures by enrollment group, age, and portion of MO HealthNet budget. Other program information was shared regarding top expenditures by drug classes, as well as specialty vs. non-specialty spending. Calloway shared information regarding other activities within MHD and the State budget. |
| **DUR Report** | Stephen Calloway stated all items from the September 2016 PA Committee Meeting were ratified by the DUR Board at their October 2016 meeting. |
| **Old Business** |
| **Implementation Schedule** | An updated copy of the Proposed Implementation Schedule for Edits, including PDL classes was included in the Members’ meeting packet and provided as a handout to those in attendance. The schedule noted the Annual PDL therapeutic classes and Clinical Edits from September/October 2016 will be implemented in January 2017. PDL decisions from December/January will be implemented April 2017. Schedules may be found on the MHD web page at <http://dss.missouri.gov/mhd/cs/pharmacy/impsched.pdf> |
| **New Business** |
| **New Drug Review** | Stephen Calloway reviewed the new drug products that were identified for the quarter July, August, September 2016 and the recommended status within the clinical program.* **Discussion –** A listing of products recommended for open access, clinical edit, preferred drug list (PDL) product, or continued prior authorization was provided in the Members’ meeting packet for discussion and action. This listing was also provided as a handout to all attending.
* **Public Hearing –** Patrick Moss, Sarepta presented information on Exondys 51.
* **Decision –** Members voted to accept the new drug recommendations as presented. (See Roll Call Vote)
 |

|  |
| --- |
| **Clinical Edits** |
| **Short-Acting and Short-Acting Combination Narcotics Clinical Edit** | * **Discussion –** Mr. Calloway reviewed the Clinical Edit proposal, along with transaction information on projected claims and call center impact. The Edits include a 7-Day Supply limit for New Opiate prescriptions and a reduction in morphine-equivalent dosages. February 2017 was proposed for implementation of the edit, but the date is flexible.
* **Public Hearing –** No comments entered.
* **Decision –** After discussion of proposed criteria the clinical edit was approved. (See Roll Call Vote)
 |

|  |  |
| --- | --- |
| **Botulinium Toxin Type A** | * **Discussion –** Dr. Roaseau reviewed the Clinical Edit proposal, including approval and denial criteria.
* **Public Hearing –** No comments entered.
* **Decision –** The Committee voted to accept this clinical edit as presented. (See Roll Call Vote)
 |
| **Preferred Drug List (PDL) Annual Renewals** |
| **Alzheimer’s Agents** | * **Discussion –** Mr. Calloway stated there are no changes recommended for this class.
* **Public Hearing –** No comments were entered.
* **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
 |
| **Antiemetic Agents** | * **Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents. One drug previously included in this category was moved to the GI Motility Agents PDL.
* **Public Hearing –** No Comments Entered.
* **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
 |
| **Cox-II Inhibitor Agents** | * **Discussion –** Mr. Calloway stated there are no changes recommended for this class.
* **Public Hearing –** No comments entered.
* **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
 |
| **Fibromyalgia Agents** | * **Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.
* **Public Hearing –** No comments entered.
* **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
 |
| **GI Motility Agents** | * **Discussion –** This is a new PDL Class and incorporates drugs that were previously part of clinical edits. Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.
* **Public Hearing –** Taylor Bradshaw, Allergan provided information on Linzess and inquired about diagnosis criteria for Viberzi.
* **Decision –** The Committee voted to accept this PDL edit as presented, pending clarification of the diagnosis criteria for Viberzi. (See Roll Call Vote)
 |
| **Long-Acting Narcotics** | * **Discussion –** Mr. Calloway stated there are no changes recommended for this class.
* **Public Hearing –** Jerod Downing, Purdue Pharma, LP provided information on Hyslinga ER.
* **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
 |
| **Neuropathic Pain Agents** | * **Discussion** – Mr. Calloway stated there are no changes recommended for this class.
* **Public Hearing** – No comments entered.
* **Decision** – The Committee voted to accept the PDL edit as presented. (See Roll Call Vote)
 |
| **Non-Ergot Dopamine Receptor Agonists** | * **Discussion –** Mr. Calloway stated there are no changes recommended for this class.
* **Public Hearing –** No comments entered.
* **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
 |
| **NSAID Agents** | * **Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.
* **Public Hearing –** No comments were entered.
* **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
 |

|  |  |
| --- | --- |
| **Opiate Dependence Agents** | * **Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.
* **Public Hearing –** Rose Mullen, Alkermes provided updated product information on Vivitrol.
* **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
 |
| **Opiate Emergency Reversal Agents** | * **Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agent. This was first proposed as a Clinical Edit at the September 2016 Drug PA Committee meeting.
* **Public Hearing –** No comments were entered.
* **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
 |
| **Sedative Hypnotic Agents** | * **Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agent.
* **Public Hearing –** No comments were entered.
* **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
 |
| **Skeletal Muscle Relaxants** | * **Discussion –** Mr. Calloway stated there are no changes recommended for this class.
* **Public Hearing –** No comments were entered.
* **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
 |
| **Serotonin Receptor Agonists (Triptans)** | * **Discussion –** Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agent.
* **Public Hearing –** No comments were entered.
* **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
 |
| **Tramadol-Like Agents** | * **Discussion –** Mr. Calloway stated there are no changes recommended for this class.
* **Public Hearing –** No comments were entered.
* **Decision –** The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
 |
| **Proposed New Preferred Drug Classes** | Stephen Calloway announced that several new PDL Categories or breakouts from existing Drug Classes for 2017. These included **Topical Agents for Actinic Keratosis, Antipsoriatic Agents (Oral)** |
| **Preferred Drug List Announcement** | A handout of therapeutic categories to be reviewed for inclusion on the Preferred Drug List for the next phase and March/April Advisory meetings was included in the meeting packet. This handout was also provided to all attendees and will be posted to the Division's web page. |
|    |
| **Xerox Update** | Luke Boehmer, Pharm D reviewed clinical edits, utilization data and trends for ADHD. Dr. Boehmer also discussed the different reasons for denials. |
| **Program Utilization: Top 25 Drugs Summary** | Dr. Boehmer reviewed the Top 25 Drugs Summary Reports for the 4th quarter 2015 through the 3rd quarter2016. Two versions were presented: one report ranked drug spend by dollars and the other by utilization/claims. |
| **Call Center Statistics/ CyberAccess Reports** | A handout detailing pharmacy help desk call center activity was provided for all attending. Cyber Access Active User Counts and Logging Information reports detailing activity were shared. Dr. Boehmer reviewed how many sites/physical locations are trained and have access to CyberAccess. Reports also detailed the number and type of prescribers and active users on CyberAccess. |
| **Adjourn** | The meeting was adjourned. The next meeting of the Drug Prior Authorization Committee is scheduled for Thursday, **March 16, 2017** at the **Department of Natural Resources, 1101 Riverside Drive, Lacharrette/Nighingale Rooms**. Attendees were advised to check the [calendar of events](http://www.dss.mo.gov/mhd/global/pages/calendar.htm) on the MHD website for meeting location changes over the next few months. (See attached roll call) |

Roll Call Votes – December 15, 2016

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Member** | **Minutes** | **New Drug Review** | **Short-Acting/ Short Acting Combination Narcotics Clinical Edit** | **Botulinium Toxin Type A Clinical Edit** | **Alzheimer’s Agents** | **Antiemetic Agents** | **Cox-II Inhibitor Agents** |
| **Conrad Balcer, D.O.** | Y | Y | Y | Y | Y | Y | Y |
| **Pat Bryant, Pharm D** | Y2 | YM | Y | Y | Y | Y | Y2 |
| **Laura Kingsley, Pharm D** | Y | Y | Y | Y | Y2 | Y2 | Y |
| **Laine Young-Walker, M.D.** | YM | Y | Y2 | Y2 | YM | YM | Y |
| **Morgan Sperry, Pharm D** | - | - | - | - | - | - | - |
| **Jennifer Kemp-Oestriech, Pharm D** | Y | Y2 | YM | YM | Y | Y | YM |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Member** | **Fibromyalgia** | **GI Motility Agents** | **Long-Acting Narcotics** | **Neuropathic Pain Agents** | **Non-Ergot Dopamine Receptor Agonists** | **NSAID****Agents** | **Opiate Dependence Agents** |
| **Conrad Balcer, D.O.** | Y | Y | Y | Y | Y | Y | Y |
| **Pat Bryant, Pharm D** | Y2 | Y | YM | Y2 | Y | Y2 | Y2 |
| **Laura Kingsley, Pharm D** | Y | Y | Y | Y | Y | Y | Y |
| **Laine Young-Walker, M.D.** | YM | Y2 | Y | Y | YM | YM | YM |
| **Morgan Sperry, Pharm D** | - | - | - | - | - | - | - |
| **Jennifer Kemp-Oestriech, Pharm D** | Y | YM | Y2 | YM | Y2 | Y | Y |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **Opiate Emergency Reversal Agents** | **Sedative Hypnotic Agents** | **Skeletal Muscle Relaxants** | **Serotonin Receptor Agents (Triptans)** | **Tramadol-Like Agents** | **Adjourn** |
| **Conrad Balcer, D.O.** | Y | Y | Y | Y | Y | Y |
| **Pat Bryant, Pharm D** | YM | YM | Y | Y2 | Y | YM |
| **Laura Kingsley, Pharm D** | Y | Y | Y | Y | Y2 | Y |
| **Laine Young-Walker, M.D.** | Y2 | Y2 | Y2 | Y | YM | YS |
| **Jennifer Kemp-Oestriech, Pharm D** | Y | Y | YM | YM | Y | Y |
| **Morgan Sperry, Pharm D** | - | - | - | - | - | - |